GENINVO launches its latest offering - Innovation As A Service


Posted September 1, 2022 by Geninv0

GENINVO, a leading provider of life science product and business solutions announced the launch of its new, on-demand service: Innovation as a Service.

 
GENINVO, a leading provider of life science product and business solutions announced the launch of its new, on-demand service: Innovation as a Service.

GENINVO, a leading provider of life science product and business solutions announced the launch of its new, on-demand service: Innovation as a Service.

GENINVO has recognized various challenges the pharmaceutical industry faces, especially in the wake of the pandemic. The need to expedite clinical trials, upcoming regulatory challenges, and the ever-changing technological landscape are hard to keep up with.

Keeping these challenges in mind, GENINVO has introduced a new engagement model - Innovation as a Service. People, process’, and technology will be key elements in this offering. Resources will be extended to help address challenges of technology and domain level expertise to build long term solutions and provide necessary support.

Engagement under this model will give an opportunity to meet with several Subject Matter Experts, Senior Solution Architects, UI/UX designers, Data Scientists, Technical Leaders, and Managers. This model will also enable to promptly define innovative products and turn them into working prototypes, and finally into Minimum Viable Products (MVP).

GENINVO will be assisting throughout the technology and operations sides of the journey and help our customer maintain the organization’s focus on the scientific aspects. “The primary focus of providing Innovation as a service offering is to utilize the best of both sides and to create a solution beyond the limits of where the human brain stops thinking.

Our expert teams follow an end-to-end approach, dedicating the necessary supplies to develop an accurate resolution. By fully offering our expertise, resources, and subject matter specialists, we build an effective product that caters to the missing pieces our customers need to be filled.

This is also how we personalize our client experience, and maintain momentum as well as balance, to deliver augmented and efficient results” says Shweta Shukla, CEO at GENINVO.

About GENINVO GENINVO is the go-to partner for those looking to better leverage technology in the life science industry. With expertise in life sciences, leading-edge technologies, and software development GENINVO can provide innovative solutions and services to its various sponsors. GENINVO Mission Statement - "We strive to provide innovative technology solutions for life science/pharmaceutical industries''.

For more information, visit https://www.geninvo.com/


About Geninvo technologies
GENINVO is the go-to partner for life science industry. We deliver Innovative software solutions and Data Science services to our clients. Currently, it takes pharmaceutical companies a decade or more in the drug discovery lifecycle, whereas at GENINVO, we have made it our mission to enable our Life Sciences clients with the speed and efficiency in the Drug Development process. Our technology powered solutions and tools create quantifiable business impact and cause unprecedented acceleration in the Drug Development process. GENINVO is proud to have a unique combination of expertise in various domains like - life sciences, leading edge technologies, software development, data-engineering practices, cloud expertise, and research in artificial intelligence, which truly helps to bring life-changing treatments to patients faster. You can find us in several locations in: USA, Canada, Europe, UK, and India.

Contact info
Email – [email protected], +1 309-807-5006
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Geninvo Technologies Pvt. Ltd
Phone 3098075006
Business Address 1408 East Empire Street
Country United States
Categories Software
Tags artificial intelligence , custom software development , data anonymization , life science
Last Updated September 1, 2022